Rochelle Walensky, Director of the Facilities for Illness Management and Prevention, appears on previous to a Senate Well being, Schooling, Labor, and Pensions Committee listening to on Capitol hill in Washington, D.C., July 20, 2021.
Stefani Reynolds | Pool | Reuters
CDC Director Dr. Rochelle Walensky stated Friday she is standing by an advisory committee’s resolution to maintain Johnson & Johnson’s Covid-19 vaccine in the marketplace regardless of a uncommon, however severe, facet impact that has prompted blood clots in some folks.
“Given the present state of the pandemic, each right here and world wide, any vaccination is best than no vaccination,” Walensky stated throughout a press briefing by the White Home Covid-19 response staff. “People who’re unable or unwilling to obtain an mRNA vaccine will proceed to have entry to Johnson & Johnson’s Covid-19 vaccines.”
The company’s Advisory Committee on Vaccine Practices on Thursday unanimously really helpful Pfizer and BioNTech’s or Moderna’s Covid-19 vaccines, which use mRNA know-how that hasn’t been linked to the blood clots, over J&J’s, which makes use of a extra conventional virus-based know-how. The Facilities for Illness Management and Prevention confirmed 54 circumstances of largely youthful girls who developed blood clots with low blood platelet ranges — a brand new situation known as thrombosis with thrombocytopenia syndrome, or TTS — after receiving J&J’s pictures. Of these circumstances, 36 required therapy in intensive care.
The panel’s presentation of the information confirmed the best rick of TTS is amongst females 30 to 49 years of age.
The committee voted unanimously on a preferential advice making the J&J vaccine accessible to those that are unable or unwilling to obtain the opposite two vaccines.